Specific transport
proteins package classical neurotransmitters into vesicles so that their release can be regulated by neural activity. Previous studies have suggested that a single activity mediates the vesicular transport of monoamines in the adrenal gland, brain, and other tissues such as mast cells and platelets.
However, molecular cloning has recently identified two vesicular transporters for monoamines. Although the predicted proteins are closely related in sequence, they show a range of differences in their physiologic and pharmacologic properties.
To clarify further the biological significance of the observed functional differences, we have generated anti-peptide antibodies to the C-termini of the two transporters and used them to determine the distribution and localization of the proteins in the rat. We have detected expression of vesicular monoamine transporter 1 (VMATl) in adrenal chromaffin cells but not in neural cells. Interestingly, some adrenal chromaffin cells also express VMATS but the amount of VMATP relative to VMATl appears much lower than in the bovine adrenal gland. In contrast, sympathetic ganglion cells express only VMATS, as do enteric neurons and enterochromaffin-like cells of the stomach. Thus, although adrenal chromaffin cells, sympathetic and enteric neurons derive from the neural crest, they express different vesicular amine transporters.
In the CNS, dopamine, norepinephrine, epinephrine, 5HT, and histamine cell groups all express VMATS. These findings are consistent with the functional characteristics of VMATl and VMATS and help to explain several classic pharmacological observations. VMAT24m-munoreactivity is generally stronger in cell bodies, proximal dendrites and axonal processes, indicating the potential for monoamine storage at each of these sites. The regulated exocytotic release of neurotransmitter in response to neural activity requires storage within intracellular vesicles. For classical transmitters that are synthesized in the cytoplasm or appear there after removal from the synapse by plasma membrane reuptake, storage depends on active transport into the vesicle. Four distinct vesicular transport activities have been identified, one for monoamines, a second for acetylcholine, a third for glutamate, and a fourth for GABA and glycine (Sudhof and Jahn, 1991; Edwards, 1992) . Due to the robust activity expressed by bovine chromaffin granules, vesicular amine transport has served as a paradigm for the vesicular transport of neurotransmitters. The chromaffin granule transporter uses the pH gradient across the vesicle membrane generated by the vacuolar H+-ATPase to drive uptake and so acts as a proton exchanger (Johnson, 1988) . In contrast to the plasma membrane transporters for dopamine, norepinephrine and 5-HT which show relative substrate specificity (Amara and Kuhar, 1993) , the chromaffin granule transporter recognizes the different monoamine transmitters with roughly similar affinity (Johnson, 1988) . The drugs reserpine and tetrabenazine potently inhibit vesicular amine transport and have implicated an analogous transport activity in the storage of monoamines in the CNS (Scherman, 1986) . In addition, vesicular amine transport mediates the storage of serotonin by platelets (Fishkes and Rudnick, 1982) and of histamine by mast cells, indicating a role outside the adrenal gland and the nervous system. Selection in the neurotoxin N-methyl-4-phenylpyridinium (MPP') has recently led to the molecular cloning of two vesicular monoamine transporters (Liu et al., 1992a) . MPP' is the active metabolite of 1 -methyl-4-phenyl-1,2,3$tetrahydropyridine (MPTP) that produces a syndrome with remarkable clinical and pathological similarity to idiopathic Parkinson's disease (Langston et al., 1983) . MPTP selectively injures monoamine neurons because these cells express plasma membrane amine transport activities that accumulate the active metabolite (Javitch et al., 1985) . Inside the cell, MPP' enters mitochondria and inhibits respiration (Ramsay and Singer, 1986; Krueger, 1990) . The chromaffin granule amine transporter protects the cell by sequestering the toxin in vesicles, away from its primary site of action in mitochondria (Liu et al., 1992a; del Zompo et al., 1993) . The amino acid sequence of the transporter predicts twelve transmembrane domains and shows similarity to a class of bacterial antibiotic resistance proteins including the tetracy-cline resistance genes from pBR322 and TnlO as well as a bacterial multi-drug resistance transporter (Liu et al., 1992b) . The ability to protect against MPP' and the apparent evolution from ancient detoxification systems raise the possibility that vesicular amine transport serves two functions in the nervous system, one in packaging transmitter for regulated release and the other in neural protection. Although no exogenous toxin has been identified in the idiopathic disease, the endogenous transmitter dopamine shows considerable toxicity (Rosenberg, 1988; Michel and Hefti, 1990; Cubells et al., 1994) and vesicular amine transport may therefore act to protect against the endogenous transmitter by accumulating it from the cytoplasm. Northern analysis showed expression of the chromaffin granule transporter in only the adrenal gland (Liu et al., 1992b) . A distinct but closely related cDNA has been isolated from a brainstem cDNA library (Liu et al., 1992b) and a basophilic leukemia cell line (Erickson et al., 1992) . These two vesicular monoamine transporters differ in terms of their functional properties. The transporter expressed predominantly by the adrenal gland (originally termed chromaffin granule amine transporter, now VMATl)
has an approximately threefold lower affinity for most monoamine substrates than the protein expressed in the CNS (originally termed synaptic vesicle amine transporter, now VMAT2) (Peter et al., 1994) . In addition, VMATI has a lower turnover number than VMAT2.
However, the most striking difference in substrate preference by the two transporters concerns histamine: VMATl recognizes histamine very poorly whereas VMAT2 recognizes histamine with approximately 1 OO-fold higher affinity (Peter et al., 1994) . In terms of pharmacologic sensitivity, tetrabenazine and psychostimulants such as methamphetamine inhibit VMAT2 much more potently than VMATl (Peter et al., 1994) . Thus, the two transporters show substantial differences in their physiological properties as well as in their pharmacology.
To further clarify the significance of these differences in transport activity for neural protection as well as synaptic transmission, we have raised anti-peptide antibodies to the C-termini of both proteins and have determined their distribution and cellular localization.
Materials and Methods
Peptide synthesis and nntibody pro&&on.
The peptide (C)SYPIGDD-EESESD was synthesized manually and coupled through an N-terminal cysteine to keyhole limpet hemocyanin (KLH) using m-maleimidobenzoyl N-hvdroxvsuccinimide ester (MBS) . The coniugated peptide (250 Kg) was emulsified in' Freund's complete adjuvan; and injected intradermally into female adult rabbits. Six weeks later, antibody production was boosted with the subcutaneous injection of 100 pg conjugated peptide emulsified in incomplete Freund's adjuvant. Twelve days after the boost, the animals were bled through an ear vein and the antibody titer assessed using a solid-phase ELISA . Animals producing anti-peptide antibodies were boosted further with 100 kg of conjugated peptide at 6 week intervals. The sera were collected 2 weeks after each boost. The anti-peptide antibodies were purified on a peptide affinity column of epoxy-activated sepharose 6B (Pharmacia). To demonstrate specificity on Western blots, the antibody was diluted 1: 100 in 500 ~1 Tween 20/phosphate-buffered saline containing 1 mg peptide and incubated overnight at 4°C. For immunohistochemistry, the antibody was diluted at 1500 or 1:lOOO in 0.5% Triton X-loo/phosphate buffer with IO-' M peptide and incubated overnight at 4°C. Peptides used were the same as those used for antibody production.
Western blot analysix
Postnuclear supernatants were prepared from wild-type and transfected CHO cells and approximately 25 kg protein separated by electrophoresis through 10% SDS-polyacrylamide containing 6 M urea. The gels were then transferred to nitrocellulose with a semidry electrotransfer apparatus and the filters probed as described previously . Briefly, the filters were blocked in phosphate-buffered saline containing 0. I % Tween-20 (TBS) and 5% nonfat dry milk, incubated in TBS containing primary antibody and I % nonfat dry milk at a dilution of 1:lOOO for 1 hr at room temperature, washed three times in TBS, and incubated with secondary antibody conjugated to peroxidase (Vector) and the immune complexes visualized by chemiluminescence (Amersham).
Tissue prepavurion. Adult albino Sprague-Dawley rats were used for the studies. The animals were housed in a standard environment with free access to food and water. Experimental procedures were consistent with those stipulated in the NIH Guide and approved by the Veterans Administration Animal Research Committee. For brain, spinal cord, superior cervical ganglion, submandibular and adrenal gland, rats were deeply anesthetized with 30% chloral hydrate and perfused through the heart with 4% paraformaldehyde (PFA) in 0.1 M phosphate buffer, pH 7.4 (PB). Tissue specimens were posttixed in the same solution for I-2 hr at room temperature. Following fixation, tissue was stored at 4°C in 25% sucrose/PB. The brain and spinal cord were sectioned with a sliding microtome at 30 pm and the sections were stored free-floating in PB at 4°C. The superior cervical ganglion, submandibular gland, and adrenal gland were cut with a cryostat at 12-15 pm, the sections collected onto slides coated with chrom alum and gelatin and stored at -20°C. For collection of the gut tissue, rats were anesthetized with halothane and decapitated. The stomach and small intestine were dissected out fresh, pinned onto wax plates, fixed overnight in 4% PFA/ PB at 4°C and after incubation in 25% sucrose/PB for 12-24 hr, sectioned with a sliding microtome at 30 pm and stored in PB at 4°C.
Immunohistochemistry.
VMAT-I and VMAT-2 antibodies were used at a final dilution of 1:500 and l:lOOO, respectively. Tissue sections were processed for immunohistochemistry using the avidin-biotin peroxidase method (Vector). Briefly, sections were washed in PB, pretreated in 0.1-l% H20, for 15 min and incubated in the primary antibody, 10% normal goat serum, and 0.5% Triton X-100 in PB for 18-24 hr at 4°C. The sections were then incubated in biotinylated goat anti-rabbit secondary antibody diluted 1:lOO in 10% normal goat serum/PB and Triton X-100, washed and subsequently incubated in an avidin-biotin complex conjugated to horseradish peroxidase. Sections were then washed, incubated in 3',3'-diaminobenzidine (DAB) with 0.01% H,O,. Free floating sections were mounted onto slides coated with gelatin. All of the tissue samples were incubated in 0.5% osmium tetroxide for 10 set, dehydrated through graded alcohols, cleared in xylene and coverslipped with Krystalon. The specificity of the stain was assessed by (1) substitution of the primary antibody with nonimmune serum and (2) by preadsorption of the primary antibody with the peptide antigen as described above for antibody production.
Results
To determine the distribution of vesicular monoamine transporters VMATl and VMAT2, we raised polyclonal antibodies to peptides derived from the sequence predicted by the two cDNAs (Liu et al., 1992b) . In both cases, peptides derived from the C-terminus of the proteins and coupled through an N-terminal cysteine to KLH produced antibodies with the highest titer as determined by ELISA. Purification of the sera by affinity chromatography reduced background staining. We have previously reported Western analysis showing that the antiserum to VMATl recognizes a protein of -55 kDa in transfected but not wildtype CHO cells . Adsorption of the VMATl antiserum with the peptide sequence used for antibody production abolished immunoreactivity in tissue sections . The antibody to VMAT2 similarly recognizes a protein of -5.5 kDa in CHO cells transfected with VMAT2, but not wild-type cells (Fig. 1 ). Higher molecular weight forms are due to glycosylation unpublished observations) . However, the source of additional immunoreactive bands migrating more rapidly than the strongest VMAT2 band remains unclear. They did not vary with the inclusion of protease inhibitors (data not shown) and did not appear on immunoprecipitation (Y.L. and R.H.E., unpublished observations). A background band of roughly equivalent intensity appears in both transfected and wild-type cells, confirming that similar amounts of protein 29 - Figure I . VMAT2 antibody does not recognize VMATl Postnuclear supernatants (-25 kg) from wild-type CHO cells and CHO cells stably transfected with VMATl and VMAT2 were separated by electrophoresis through 10% SDS-polyacrylamide and electroblotted to nitrocellulose. An antibody generated against a C-terminal peptide predicted from the sequence of VMAT2 recognizes a series of bands in cells expressing VMAT2 but not cells expressing VMATl or wild-type cells. The predominant species migrates at approximately 55 kDa (arrow) and the other species were not influenced by the presence or absence of protease inhibitors (data not shown). A consistent background band confirms that roughly equal amounts of protein were loaded in each of the three lanes.
were present in each lane. Finally, the VMAT2 antibody does not recognize VMATl in transfected cells (Fig. 1) . Thus, the VMAT2 antiserum shows both sensitivity and specificity.
Adrenal gland Although Northern analysis originally showed expression of VMATl but not VMAT2 mRNA transcripts by the rat adrenal gland, in situ hybridization with oligonucleotide probes has suggested that ganglion cells located within the gland express VMAT2 (Mahata et al., 1993) . In addition, purification and molecular cloning of an amine transporter from bovine chromaffin granules has indicated a protein with greater similarity to rat VMAT2 than VMATl (Stern-Bach et al., 1990 Krejci et al., 1993; Howell et al., 1994) . In previous studies, we found that essentially all adrenal medullary cells in the rat express VMATl , suggesting that the adrenal contains predominantly VMATl. However, the antibody to VMAT2 also stained some cells in the adrenal medulla. Whereas VMATl immunoreactivity is strong in the adrenal medulla and occurs in all chromaffin cells (Fig. 2B) , adjacent sections show that some chromaffin cells also immunostain for VMAT2 ( Fig. 2A) , indicating that a small proportion of adrenal medullary cells are likely to express both vesicular amine transporters. VMAT2-im- munoreactive cells have the typical morphology of chromaffin cells, and do not have the large cell body and processes characteristic of ganglion cells. However, since we did not observe ganglion cell staining with either antibody, the results do not exclude expression of VMAT2 by ganglion cells but rather indicate that the majority of VMATZimmunoreactive cells in the adrenal gland are chromaffin cells. PNS Sympathetic nervous system. Similar to adrenal chromaffin cells, sympathetic ganglion cells also derive from the neural crest and express monoamine transmitters. By immunocytochemistry, sympathetic ganglion cells do not express VMATl. In contrast, we detect VMAT2-immunoreactive processes in all peripheral tissues evaluated in this study. Figure 3B shows VMAT2-immunoreactive small diameter fibers and varicosities that are typical of sympathetic nerves in the submandibular gland. Figure  4C shows the VMAT2-immunoreactive innervation of blood vessels which is likely to be derived from sympathetic ganglion cells. We also evaluated the superior cervical ganglion. Ganglion cells show no detectable reaction for VMATl, but strong reaction for VMAT2 (Fig. 3A) , consistent with the VMAT2-immunoreactive staining of peripheral processes. Thus, postganglionic sympathetic neurons differ from adrenal chromaffin cells in the expression of vesicular amine transporters.
Gastrointestinal tract. Dense networks of VMAT2-immunoreactive fibers innervate the blood vessels (Fig. 4C) . VMAT2 immunoreactivity is also found in the dense, varicose processes of the enteric plexuses and interconnecting strands (Fig. 4A ) and in some intrinsic neurons. Furthermore, a large number of gastric mucosal cells in the fundus and corpus are VMAT2-immune: reactive (Fig. 4B) . These cells are probably enterochromaffinlike (ECL) cells as indicated by their location and morphology. Consistent with previous work showing that VMAT2 has approximately two orders of magnitude higher affinity for histamine than VMATl (Peter et al., 1994) , these histamine-containing cells in the stomach express VMAT2 (Fig. 4B) . Preadsorption of the VMAT2 antiserum with the peptide used to generate it also eliminated the staining (Fig. 40) , further demonstrating the specificity of the immunoreaction for this vesicular amine transporter. In contrast, we did not detect any expression of VMATl by enteric neurons, although occasional endocrine cells in the gastrointestinal did immunostain for VMATl (data not shown).
CNS
All monoamine cell groups in the central nervous system express VMAT2 immunoreactivity and their processes are distributed along the entire neuraxis. The dopamine cells including those in the dorsal premammillary nucleus, substantia nigra, pars compacta and ventral tegmental area contain VMAT2 (Fig. 5) . Norepinephrine cell groups including A5, the locus coeruleus and subcoeruleus also express VMAT2 (Fig. 6) . Adjacent sections stained with an antibody to tyrosine hydroxylase showed the identical pattern of immunoreactivity in these dopaminergic and noradrenergic populations (data not shown). The serotoner- Scale bar: A, 50 pm; B, 100 pm; C, 300 pm. gic cell groups including the dorsal and median raphe and the raphe pallidus also contain VMAT2-immunoreactive cells (Figs. 7, 8) . Adjacent sections stained with an antibody to 5-HT showed an identical pattern of immunoreactivity in these cell groups (data not shown). Finally, epinephrine cell populations such as the Cl group also express VMAT2. In addition, the antiserum recognizes monoamine-containing fibers including the medial forebrain bundle, the dorsal catecholamine bundle and central tegmental tract. Dopamine cell groups. Cells in the substantia nigra, pars compacta show much greater susceptibility to the neurotoxin MPTP and to idiopathic Parkinson's disease than other dopamine populations (Langston et al., 1983) . Immunocytochemistry shows strong staining for VMAT2 in both the substantia nigra and the immunoreactivity in the serotonergic dorsal raphe nucleus (DR). mlf, medial longitudinal fasciculus; 4v, fourth ventricle. Scale bar, 100 brn. ventral tegmental area (Fig. 5A) . The relatively MPTP-resistant dopamine groups such as those in the hypothalamus as well as dorsal midbrain also immunostain for VMAT2. VMAT2 immunoreactivity is present in the cytoplasm and localized most heavily to the soma, proximal dendrites and axonal processes (Fig. 5B,C) . The pattern of staining differs from the more diffuse cytoplasmic pattern observed with tyrosine hydroxylase that includes a larger proportion of the dendrites (data not shown).
Noradrenaline, SHT, and histamine cell groups. Cell bodies and processes in the noradrenergic locus coeruleus and subcoeruleus immunostain strongly for VMAT2 (Fig. 6A) . In addition, the norepinephrine cell group A5 expresses VMAT2 (Fig. 6B) . Serotonergic groups including the dorsal raphe, median raphe, and raphe pallidus nuclei also stain strongly for VMAT2 (Figs. 7, 8) . We find that histamine-containing neurons in the posterior hypothalamus express VMAT2 (Fig. 9) . Epinephrine cells are also likely to stain for VMAT2 (data not shown). For example, cells in the solitary nucleus known to express phenylethanolamine-N-methyltransferase (PNMT) (Ruggiero et al., 1994) are in the same position as cells expressing VMAT2. In contrast, we detected no immunoreactivity for VMATl in the brain (data not shown).
Olfactory bulb. The olfactory bulb contains a large number of dopaminergic neurons in the glomerular layer (Halasz et al., 1977) . Earlier in situ hybridization studies had shown no VMATl or VMAT2 mRNA-containing cells (Liu et al., 1992b) . Immunocytochemical studies also fail to demonstrate either VMATl or VMAT2 immunoreactivity in the olfactory bulb (data not shown). Indeed, we have screened a cDNA library prepared from the olfactory bulb with both cDNAs and found no positively hybridizing signal. As interneurons, these cells may express lower levels of transporter than projection neurons in the brainstem. However, we have detected VMAT2 mRNA and VMAT2 immunoreactivity in other interneuron populations such as the retina (data not shown).
Terminal jields. Since localization of the vesicular amine transporters determines the site of storage, it was thus of particular interest to examine the immunoreactivity of VMAT2 in terminal fields. Axonal fibers containing VMAT2 were present along the entire neuraxis. For example, the cortex contains small immunoreactive fibers with periodic varicosities (Fig. 1OA) . In the basal ganglia, the projections are very fine and frequently difficult to discern as discrete processes (Fig. 10s) . As noted above, the dendrites of substantia nigra neurons stain for VMAT2 but at reduced levels compared to cell bodies (Fig. 5C ). On the other hand, dendrites of neurons in the locus coeruleus and dorsal raphe stain strongly for VMAT2 (Figs. 6,7) . Neuropil in the ventromedial hypothalamus stain particularly strongly (Fig. 100 
Discussion
The antibodies that we have raised appear specific for VMATl and VMAT2. The peptides used to generate them derive from not catecholamine biosynthetic enzymes (Schalling et al., 1988) , suggesting a cholinergic rather than aminergic phenotype.
Sympathetic ganglion cells express VMAT2. Immunostaining reveals expression in both peripheral processes and cell bodies in the ganglion. Similarly, some enteric neurons in the digestive tract express VMAT2 immunoreactivity. Thus, although adrenal chromaffin cells, postganglionic sympathetic neurons and the enteric nervous system derive from the neural crest, they express distinct vesicular amine transporters. Since all chromaffin cells stain for VMATl, the clusters of VMAT2-immunoreactive chromaffin cells in the adrenal medulla suggest that both transporters are expressed in the same cells and may therefore represent either an intermediate in the pathway of differentiation or an intermediate mature phenotype. The expression of both VMATl and VMAT2 by some chromaffin cells in the adrenal medulla raises the possibility that steroids derived from the adrenal cortex may influence their phenotype. However, glucocorticoids activate differentiation toward the chromaffin cell and away from the sympathetic ganglion cell pathway (Anderson, 1993) . Alternatively, other environmental cues perhaps derived from the adrenal cortex may influence the differentiation of these cells. In any case, the two vesicular amine transporters provide useful, additional markers for the alternative fates of differentiation into chromaffin cells versus ganglion cells.
Expression of VMATl and VMAT2 in the adrenal gland of the rat appears to differ from expression in the adrenal gland of cattle. Using bovine chromaffin cells as a source, Schuldiner and colleagues purified a vesicular amine transporter with the high sensitivity to tetrabenazine which is suggestive of VMAT2 (Stern-Bach et al., 1990) . N-Terminal peptide sequence analysis followed by cDNA cloning showed a closer relationship of this transporter to rat VMAT2 than rat VMATl (Stern-Bach et al., 1992; Krejci et al., 1993; Howell et al., 1994) . Interestingly, purification had yielded two proteins differing in their isoelectric points. Molecular cloning has shown the existence of bovine VMATl (Gasnier et al., 1994) as well as bovine VMAT2, raising the possibility that the two isoforms represent VMATI and VMAT2. In any case, the ability to purify VMAT2 from the bovine adrenal medulla clearly indicates that VMAT2 constitutes a large proportion of the total vesicular amine transporters in this tissue. The miniscule amount of VMAT2 present in the rat adrenal suggests that the relative expression of the two transporters in the adrenal gland would vary considerably in different species and raises the possibility that varying proportions of VMATl and VMAT2 confer physiologically significant differences in function.
The expression of VMATl by adrenal chromaffin cells and VMAT2 by ganglion cells has implications for the release and turnover of monoamines by these two cell populations. VMATl has a lower affinity than VMAT2 for most monoamine substrates and also has a lower turnover number (Peter et al., 1994) . Thus, VMAT2 is more adapted to the rapidly recycling synaptic vesicles at sympathetic nerve terminals whereas VMATl may function adequately to fill the slowly recycling dense core vesicles in chromaffin cells. In addition, the transporters differ in pharmacology. Reserpine potently inhibits both VMATl and VMAT2 but tetrabenazine inhibits VMAT2 much more potently than VMATl. Interestingly, reserpine depletes both central and peripheral monoamine stores whereas tetrabenazine has been known to have a more selective central effect (Carlsson, 1965) . This may in turn account for the reduced side-effect of hypotension observed with tetrabenazine as opposed to reserpine divergent regions at the C-terminus of the two transporters. The antisera detect VMATl in the adrenal medulla and VMAT2 in known monoamine cell groups in the nervous system. Further, the VMATl antibody does not recognize VMAT2-immunoreactive populations in the brain and the VMAT2 antibody does not recognize VMATl on Western blots. We have previously identified VMATl immunoreactivity in chromaffin cells of the adrenal medulla . Although we could not detect mRNA transcripts for VMAT2 in extracts of the adrenal gland, immunocytochemistry shows scattered immunoreactive cells. The low proportion of positive cells presumably accounts for the undetectable level of VMAT2 transcripts on Northern blots. Mahata et al. (1993) VMAT2 immunoreactivity in terminal fields. Monoamine projections in the cortex (A), caudate (B) and ventromedial hypothalamus (C) stain for VMAT2. Scale bar: A, 50 pm; B, 100 pm; C, 300 pm. (Jankovic and Orman, 1988) . Although the precise sites at which either at the transcriptional level or at the posttranslational level reserpine acts to reduce blood pressure remain uncertain, the as a result of additional potential phosphorylation sites (Erickson clinically reduced hypotensive properties of tetrabenazine Liu et al., 1992b) . VMAT2 may also contain signals combination with the known differences in pharmacology bethat sort the protein to synaptic vesicles as opposed to the signals tween VMATl and VMAT2 suggest that the adrenal medulla that sort VMATl to dense core vesicles in chromaffin cells (Liu alsb contributes significantly to the regulation of blood pressure. et al., 1994) . The anatomic distribution of VMATl and VMAT2 also coincides with known differences in substrate preference. The enterochromaffin-like cells in the stomach and histamine-containing neurons in the hypothalamus express VMAT2, and VMAT2 has an affinity for histamine in the range of the affinity for other monoamines whereas VMATl has a relatively poor affinity for histamine (Peter et al., 1994) . In addition, central nervous system monoamine cells express VMAT2 rather than VMATl. The twoto threefold higher affinity of VMAT2 than VMATl for most monoamine substrates (Peter et al., 1994) may be required for the more rapid turnover of monoamines released from synaptic vesicles rather than from chromaffin granules. Alternatively, VMAT2 may undergo more complex regulation than VMATl,
The pattern of VMAT2 expression in the CNS does not correlate with vulnerability to MPTP toxicity and idiopathic Parkinson's disease. Immunocytochemistry does not provide quantitation, but both vulnerable populations such as large dopaminergic neurons in the substantia nigra, pars compacta and resistant monoamine populations such as noradrenergic neurons in the locus coeruleus and serotonergic neurons in the raphe nuclei express high levels of VMAT2 in the cell body. Thus, reduced VMAT2 expression does not appear to account for differential susceptibility. Rather, the robust expression of VMAT2 by dopaminergic neurons in the substantia nigra remains insufficient to protect neurons in the substantia nigra.
Curiously, periglomerular neurons in the olfactory bulb that contain dopamine do not appear to express either VMATl or VMAT2. In situ hybridization showed no signal using either cDNA as probe but low levels of expression by this population of interneurons could make detection difficult. Both antibodies show no immunoreactivity and screening >lOh clones of an olfactory bulb library yielded none hybridizing with either VMATl or VMAT2 even at reduced stringency. Thus, periglomerular interneurons in the olfactory bulb either express extremely low levels of a vesicular amine transporter (perhaps consistent with their reduced terminal fields), an unrelated transporter or no vesicular amine transport at all. In the absence of vesicular amine transport activity, the regulated release of monoamines could involve reversal of plasma membrane transporters. The depolarization of electrogenic plasma membrane transporters for GABA and glutamate can produce the regulated but Ca++-independent, nonvesicular release of transmitter (Schwartz, 1987; Attwell et al., 1993) . This may also occur with a plasma membrane dopamine transporter (Sulzer et al., 1993) that, in contrast to VMAT2, has been shown to exist in dopaminergic neurons including those of the olfactory bulb (Cerruti et al., 1993) . Periglomerular intrinsic neurons dopamine do contain synaptic vesicles but relatively few and these may store the coexpressed GABA rather than dopamine (Pinching and Powell, 197 1 a-c; Mugnaini et al., 1984) . In contrast to other monoamine populations, reduced expression of vesicular amine transport by olfactory bulb interneurons may account for their apparent vulnerability in Parkinson's disease. Reduced olfactory sensation has even been suggested as an early marker of the disease (Daniel and Hawkes, 1992; Doty et al., 1992; Stern et al., 1994 ).
In addition to the level of vesicular amine transport activity, the subcellular location of the vesicular transporters will also influence the ability to protect against either an exogenous toxin such as MPTP or an endogenous toxin such as dopamine. In the case of MPP', vesicular amine transport can limit access of the toxin to mitochondria. In the case of dopamine, vesicular amine transport close to the site of synthesis or reuptake could reduce the potential for cytoplasmic oxidation of the transmitter and also protect the cell. Immunostaining shows expression of VMAT2 in both dendrites and nerve terminals. However, in contrast to tyrosine hydroxylase immunoreactivity which occurs densely throughout the cytoplasm of pars compacta cells, VMAT2 immunoreactivity is considerably stronger in the cell body than the dendrites, particularly in the more distal parts. whereas dense core vesicles also occur in dendrites and release more slowly. Monoamines differ from other classical transmitters and also appear in dense core granules in the adrenal gland (Johnson, 1988) . However, classical studies using 5-OH-dopamine as an osmiophilic false transmitter recognized by the amine transporters have suggested the storage of monoamines in smaller vesicles in the brain (Smith, 1972; Thureson-Klein, 1983; Pellegrino de Iraldi, 1992) . Since localization of the vesicular amine transporter determines the site of amine storage and hence the site and mode of amine release, it is of considerable interest to determine the location of the transporter in central neurons. In addition to its presence on somata and dendrites, VMAT2 also occurs throughout the axon and nerve terminals. For example, axonal processes were clearly seen surrounding blood vessels in the periphery as well as distributed through the basal ganglia and cortex in the brain. Indeed, VMAT%-immunoreactive fibers are seen in all regions known to contain monoamine processes. It will now be of particular interest to determine the nature of the vesicles (e.g., synaptic vesicles or dense core vesicles) expressing VMAT2 in cortical and striatal projections as well as dendrites.
In conclusion, we have raised antibodies specific for the two vesicular monoamine transporters and used these to demonstrate the distribution of the proteins in viva. We have detected VMATl in the adrenal medulla but not in neural cells. VMAT2 occurs in enteric neurons, sympathetic ganglia and central monoamine populations, with high levels expressed by dopaminergic neurons in the substantia nigra. The more rapid turnover of synaptic vesicles in neurons as opposed to chromaffin cells may require the higher affinity and faster turnover of VMAT2 rather than VMATl. Interestingly, a relatively small number of cells in the adrenal medulla appear to express both transporters and dopaminergic neurons of the olfactory bulb do not appear to express either VMATl or VMAT2, raising questions about the mode of dopamine release by these cells. In terms of subcellular distribution within neurons, VMAT2 occurs in the cell body and terminal processes but the dendrites show staining relatively restricted to the proximal segments. cellular vesicles expressing VMAT2 whereas tyrosine hydroxylase diffuses more freely throughout the cytoplasm. It follows therefore that reduced expression of the transporter in dendrites could render this part of the neuron more vulnerable. Interestingly, the dendrites of other monoamine populations in the locus coeruleus and raphe appear to stain more intensely than those in the substantia nigra, possibly accounting for their resistance to degeneration. The expression of VMAT2 in dendrites also indicates the potential for monoamine release at this site, which may serve to modulate presynaptic input (Cheramy et al., 1981) . 
